Kadcyla outperformed Herceptin regarding overall- and invasive disease-free survival in patients with HER2-positive early breast cancer that still had remaining invasive disease after undergoing neoadjuvant therapy.
Adjuvant ado-trastuzumab emtansine continued to improve overall survival and invasive disease-free survival vs trastuzumab after 8.4 years of follow-up in patients with HER2-positive early breast cancer and residual invasive disease following neoadjuvant therapy enrolled in the phase 3 KATHERINE trial.
EQS Voting Rights Announcement: JOST Werke SE
JOST Werke SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of.
EQS Voting Rights Announcement: JOST Werke SE
JOST Werke SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of.
Inovalis Real Estate Investment Trust Announces Financial Results for the Third Quarter of 2023 and the Suspension of Distributions streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.